Accelerating AAV process development with PAT-driven TFF system

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Accelerating AAV process development with PAT-driven TFF system

Ultrafiltration/Diafiltration (UF/DF) is a crucial step in bioprocessing, but within the gene therapy field, traditional methods often face challenges related to variability and lack of real-time monitoring. In this presentation we will introduce an exciting innovation that will accelerate your UF/DF and multiple stages of development.

Join us as we delve into the future of UF/DF technology and learn how the new KrosFlo® KR2i RPM AAV System, an advanced PAT-driven tangential flow filtration (TFF) system, provides unparalleled advantages for bioprocessing scalability and efficiency. Find out how to streamline your process development with a system uniquely controlled by real-time titer measurement acquired through in-line variable pathlength spectroscopy - an innovative approach that ensures a consistent and precise attainment of targeted titer results. Demonstrations of automated process control will be provided, exhibiting the system's efficacy across various final endpoints.

In this webinar you will learn:

How to effectively capture real-time capsid titer, genome titer, and empty/full ratio data
How In-line Variable Pathlength Technology (VPT) enables real-time monitoring and control of titer as a UF/DF process progresses
How automated TFF system expedites lab-scale testing with minimal manual intervention, allowing for a more rapid and efficient process
Comparative analysis of the KR2i RPM System against traditional UF/DF methods

Teva Smith

Field Application Scientist at Repligen

Teva Smith is an accomplished researcher with a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill, now specializing in bioprocessing. Currently serving as a Field Application Scientist at Repligen Corporation, Teva has amassed over 2 years and 7 months of experience in delivering onsite client demonstrations on Process Analytics Technology, with a primary focus on optimizing UF/DF, chromatography, and fill-to-finish processes. Teva plays a crucial role in post-sale customer support, overseeing implementation, process validation, SOP creation, and method transfers. Notably, Teva collaborates with the engineering division, actively participating in alpha and beta testing of new devices and providing valuable customer feedback for Research & Development projects. This commitment extends to contributing to research papers and posters on innovative device applications.

In Teva's previous role as a Product Development Research Associate at AstraZeneca, he demonstrated expertise in simulated use test inhalation trials and cGMP data collection and recording. Teva's proficiency in incorporating R statistical analysis streamlined data review and manipulation, contributing to efficient research design troubleshooting and coordination of multi-team trials. Teva's earlier experiences at the University of North Carolina at Chapel Hill and the US Environmental Protection Agency (EPA) involved conducting research on neuronal cellular adhesion molecules and independently preparing high-throughput toxicology assays, showcasing a diverse skill set in PCR, SDS-PAGE, Western Blotting, and high-throughput research methodologies. Teva Smith emerges as a driven scientific professional, blending comprehensive expertise in bioprocessing with a commitment to advancing research and development in the field.